Dr. Chiorean on Combination Therapies for Pancreatic Cancer

Video

Gabriela Chiorean, MD, associate professor of Medicine at the University of Washington, discusses adverse events of the phase I study of combination therapies for patients with pancreatic cancer.

Gabriela Chiorean, MD, associate professor of Medicine at the University of Washington, discusses adverse events of the phase I study of combination therapies for patients with pancreatic cancer.

There is an ongoing clinical trial for patients with pancreatic cancer that uses nivolumab (Keytruda) and nab-paclitaxel (Abraxane)-based combinations, explains Chiorean. It started with nivolumab and nab-paclitaxel for patients in the second-line setting and was moved to the first-line setting with nivolumab, nab-paclitaxel, and gemcitabine (Gemzar). The main goals of the study are safety and preliminary efficacy.

It was shown that nivolumab did not seem to add any significant toxicity to the chemotherapy regimen. One of the patients experienced a grade 3 dose-limiting toxicity of liver enzyme elevations, which was attributed to chemotherapy. The adverse event quickly resolved after a chemotherapy dose-reduction and nivolumab was resumed at full dose, reinforcing that it was not an immune-related event.

Related Videos
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD